Summit Therapeutics drops 11.2% after FDA rejects ivonescimab application
智通财经2026/11/16 14:51Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Affected by the FDA's rejection of the approval application for the lung cancer drug ivonescimab, $Summit Therapeutics (SMMT.US)$ fell by 11.2% during trading. The highest turnover put option recorded a price change of +26%, with a trading volume of 73 contracts. For details, please refer to the option rankings on the options page. Option prices are highly volatile, so please be aware of the risks. Click to view the SMMT option chain.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Crypto prices
MoreBitcoin
BTC
$64,278.43
-0.68%
Ethereum
ETH
$1,810.2
-0.06%
Tether USDt
USDT
$0.9991
-0.03%
BNB
BNB
$584.49
-0.96%
USDC
USDC
$1.0000
+0.02%
XRP
XRP
$0.9444
-1.34%
Solana
SOL
$70.25
-1.40%
TRON
TRX
$0.3046
-0.42%
Hyperliquid
HYPE
$66.29
-1.57%
Zcash
ZEC
$853.87
-4.30%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now